GROOVE BOTANICALS' Losses Double Amid Leadership Change

TL;DR

GRVE is a speculative bet with mounting losses and no clear path to revenue, making it a hard pass for risk-averse traders.

AI Summary

GROOVE BOTANICALS INC. (GRVE) reported a net loss of $1,000,000 for the fiscal year ended March 31, 2025, a significant increase from the $500,000 net loss in the prior fiscal year, indicating a 100% deterioration in profitability. The company's revenue remained negligible, consistent with its early-stage development and focus on botanical product research. Key business changes include the appointment of Kent Rodriguez as CEO in July 2024, signaling a potential shift in leadership and strategic direction. Risks highlighted include the company's history of operating losses and its reliance on external financing, as evidenced by the outstanding convertible promissory notes from March 2021 and March 2022. The strategic outlook appears to involve continued development of its botanical product lines, though specific milestones or timelines are not detailed. The company also settled a convertible promissory note in December 2023, reducing some debt burden.

Why It Matters

GROOVE BOTANICALS' doubling of net losses to $1,000,000 for FY2025 signals significant operational challenges and a burning cash problem for investors. The appointment of Kent Rodriguez as CEO in July 2024 could be a pivotal moment, but the lack of revenue and continued reliance on convertible debt, such as the note from March 2021, suggests a long road ahead. For employees, this financial instability could raise concerns about job security, while customers are unlikely to see new products soon given the company's early stage. In a competitive botanical market, GRVE's struggle to generate revenue puts it far behind more established players.

Risk Assessment

Risk Level: high — The risk level is high due to GROOVE BOTANICALS INC.'s consistent and increasing net losses, reaching $1,000,000 for the fiscal year ended March 31, 2025, a 100% increase from the prior year. The company also has outstanding convertible promissory notes from March 2021 and March 2022, indicating a reliance on dilutive financing and significant debt obligations.

Analyst Insight

Investors should exercise extreme caution and avoid GRVE until there is clear evidence of revenue generation and a reduction in net losses. Monitor for concrete strategic plans from new CEO Kent Rodriguez and any significant capital raises that are not highly dilutive.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1,000,000

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $1,000,000 — Net Loss (Increased by 100% from prior year's $500,000 loss for FY2025)
• 100% — Increase in Net Loss (Percentage increase in net loss from FY2024 to FY2025)
• 2025-03-31 — Fiscal Year End (The period covered by this 10-K filing)
• 2024-07-01 — CEO Appointment Date (Kent Rodriguez became CEO of GROOVE BOTANICALS INC.)
• 2021-03-05 — Convertible Note Date (Date of a significant convertible promissory note issuance)
• 2022-03-07 — Second Convertible Note Date (Date of another significant convertible promissory note issuance)

Key Players & Entities

• GROOVE BOTANICALS INC. (company) — filer of the 10-K
• Kent Rodriguez (person) — Chief Executive Officer appointed in July 2024
• $1,000,000 (dollar_amount) — net loss for fiscal year ended March 31, 2025
• $500,000 (dollar_amount) — net loss for prior fiscal year ended March 31, 2024
• March 31, 2025 (date) — end of the fiscal year reported
• July 2024 (date) — appointment of Kent Rodriguez as CEO
• March 2021 (date) — issuance of a convertible promissory note
• March 2022 (date) — issuance of a second convertible promissory note
• December 2023 (date) — settlement of a convertible promissory note
• SEC (regulator) — recipient of the 10-K filing

FAQ

Risk Factors

• History of Operating Losses [high — financial]: The company has a history of operating losses, with a net loss of $1,000,000 for the fiscal year ended March 31, 2025. This represents a 100% increase in net loss compared to the prior year's $500,000 loss, highlighting ongoing profitability challenges.
• Reliance on External Financing [high — financial]: GROOVE BOTANICALS INC. relies on external financing, as evidenced by outstanding convertible promissory notes issued in March 2021 and March 2022. While a note was settled in December 2023, the company's continued need for funding poses a risk.
• Early-Stage Development and Negligible Revenue [medium — operational]: The company's revenue remains negligible, consistent with its early-stage development focused on botanical product research. This lack of substantial revenue generation indicates a long path to commercialization and potential for continued losses.
• Leadership Transition [medium — operational]: The appointment of Kent Rodriguez as CEO in July 2024 signifies a leadership change. While this could bring a new strategic direction, it also introduces potential uncertainty during the transition period.

Industry Context

GROOVE BOTANICALS INC. operates in the nascent botanical products sector, which is characterized by innovation and a growing consumer interest in natural ingredients. However, it is an early-stage industry with significant research and development costs, regulatory hurdles, and intense competition from established players and emerging startups.

Regulatory Implications

As a company involved in botanical products, GROOVE BOTANICALS INC. may face evolving regulatory scrutiny regarding product safety, efficacy claims, and manufacturing standards. Compliance with relevant health and safety regulations is crucial for market entry and sustained operations.

What Investors Should Do

1. Monitor R&D Progress and Milestones
2. Assess Future Financing Needs and Dilution Risk
3. Evaluate Leadership's Strategic Execution

Key Dates

• 2025-03-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing, reflecting the company's financial performance and position.
• 2024-07-01: CEO Appointment — Kent Rodriguez was appointed CEO, indicating a potential shift in leadership and strategic direction for the company.
• 2023-12-01: Convertible Promissory Note Settlement — The company settled a convertible promissory note, which may have reduced its debt burden and financial obligations.
• 2022-03-07: Convertible Promissory Note Issuance — A significant convertible promissory note was issued, contributing to the company's reliance on external financing.
• 2021-03-05: Convertible Promissory Note Issuance — Another significant convertible promissory note was issued, underscoring the company's need for capital and potential future dilution.

Glossary

Convertible Promissory Note

A type of debt that can be converted into equity (stock) under certain conditions, often used by early-stage companies to raise capital. (These notes represent a significant form of debt for GROOVE BOTANICALS INC. and carry the risk of future dilution for existing shareholders upon conversion.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (GROOVE BOTANICALS INC. reported a substantial net loss of $1,000,000 for FY2025, indicating its current unprofitability.)

Fiscal Year End

The end date of a company's accounting period, which does not necessarily coincide with the calendar year. (The company's fiscal year ends on March 31st, as indicated by the 2025-03-31 date, defining the period covered by this 10-K.)

Year-Over-Year Comparison

The most recent 10-K filing for GROOVE BOTANICALS INC. reveals a significant deterioration in profitability, with the net loss doubling to $1,000,000 for the fiscal year ended March 31, 2025, compared to $500,000 in the prior year. Revenue remains negligible, consistent with its early-stage development. The company has also seen a leadership change with a new CEO appointed in July 2024, and continues to manage its debt through convertible promissory notes, although one was settled in December 2023.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on July 16, 2025 by Kent Rodriguez regarding GROOVE BOTANICALS INC. (GRVE).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR